Market Place
Sourcing Support
US FDA approves Bristol Myers` colorectal cancer therapy
22 Jun 2024 //
REUTERS
ASCO: KRAS upstarts set their sights on NSCLC market
05 Jun 2024 //
PHARMAPHORUM
KRAZATI Improves PFS In Pretreated KRAS G12C Mutant NSCLC
01 Jun 2024 //
BUSINESSWIRE
KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity
08 Apr 2024 //
BUSINESSWIRE
Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint
01 Apr 2024 //
BUSINESSWIRE
BMS touts KRAS confirmatory trial win after Amgen`s stumble
30 Mar 2024 //
FIERCE PHARMA
BMS Announces Trial Evaluating KRAZATI Meets Primary Endpoint
28 Mar 2024 //
BUSINESSWIRE
FDA Accepts sNDA for KRAZATI in Combination with Cetuximab
20 Feb 2024 //
BUSINESSWIRE
EU body endorses Mirati`s KRAS drug for lung cancer after second look
11 Nov 2023 //
PR NEWSWIRE
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration
02 Nov 2023 //
GLOBENEWSWIRE
Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC
28 Aug 2023 //
ONCLIVE
Mirati`s lung cancer drug fails to win EU regulator`s backing
22 Jul 2023 //
PRESS RELEASE
Mirati`s KRAS drug Krazati beat estimates in first full quarter
11 May 2023 //
FIERCE PHARMA
Mirati announces AdagrasibReceives Breakthrough Therapy Designation from FDA
21 Dec 2022 //
PRESS RELEASE
KRAZATI Available from Onco360 for the Treatment of NSCLC
15 Dec 2022 //
BUSINESSWIRE
QIAGEN receives FDA approval for companion diagnostic to Mirati’s KRAZATI
13 Dec 2022 //
BUSINESSWIRE
U.S. FDA approves Mirati`s lung cancer drug Adagrasib
13 Dec 2022 //
PRNEWSWIRE
Agilent ctDx FIRST Receives FDA Approval as Liquid Biopsy Companion Test
12 Dec 2022 //
BUSINESSWIRE
Mirati to focus KRAS inhibitor, Keytruda combo on low PD-L1 lung cancer
07 Dec 2022 //
FIERCEBIOTECH
Mirati Therapeutics Presents Results Evaluating Adagrasib and Pembrolizumab
05 Dec 2022 //
PRESS RELEASE
Mirati gauging sale interest of Big Pharmas — report
23 Nov 2022 //
ENDPTS
Mirati Therapeutics Sues China’s InventisBio for 99 Million RMB in Trade Secret Theft Case
17 Nov 2022 //
NALTAWREVIEW
Mirati & Aadi Partner to Evaluate the Combination of Adagrasib & Nab-sirolimus
12 Oct 2022 //
PRNEWSWIRE
Mirati Therapeutics Presents Late-Breaking Adagrasib
07 Sep 2022 //
PRESS RELEASE
Mirati KRAS data are `identical` to Amgen`s, researcher, CEO say
06 Jun 2022 //
FIERCEBIOTECH
Mirati cedes to Amgen`s Lumakras on durability in KRAS battle
28 May 2022 //
FIERCEBIOTECH
Mirati Therapeutics Submits MAA to EMA for Investigational Adagrasib in NSCLC
19 May 2022 //
BIOSPACE
Amgen`s Lumakras posts encouraging results in pancreatic cancer
16 Feb 2022 //
FIERCEPHARMA
FDA Accepts Mirati`s NDA of Adagrasib for NSCLC
15 Feb 2022 //
PRESS RELEASE
Mirati goes where Amgen won`t: KRAS drug has 41% response in GI
21 Jan 2022 //
FIERCEBIOTECH
Mirati and Verastem to evaluate lung cancer combination therapy
23 Nov 2021 //
CLINICALTRIALSARENA
Mirati sees more responses for KRAS drug in Keytruda combo
09 Nov 2021 //
ENDPTS
Mirati KRAS concerns as key adagrasib lead, COO suddenly exit
02 Nov 2021 //
FIERCEBIOTECH
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo
09 Oct 2021 //
FIERCEBIOTECH
Biogen, Mirati, mRNA players on Merck`s M&A shortlist: FT
06 Oct 2021 //
FIERCEPHARMA
David Meek takes over at Mirati with lead KRAS drug racing to an approval
21 Sep 2021 //
ENDPTS
Adagrasib, Cetuximab Combo Shows Promise in Heavily Pretreated Patients
20 Sep 2021 //
CANCERNETWORK
Mirati Presents +ve Data with Adagrasib in KRAS G12C-Mutated Colorectal Cancer
19 Sep 2021 //
PRNEWSWIRE
